A detailed history of Cgc Financial Services, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Cgc Financial Services, LLC holds 128 shares of EXEL stock, worth $2,876. This represents 0.0% of its overall portfolio holdings.

Number of Shares
128
Previous 128 -0.0%
Holding current value
$2,876
Previous $3.07 Million 1.11%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Sep 12, 2023

BUY
$18.17 - $20.48 $2,325 - $2,621
128 New
128 $2.45 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $7.23B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Cgc Financial Services, LLC Portfolio

Follow Cgc Financial Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cgc Financial Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cgc Financial Services, LLC with notifications on news.